S&P 500   4,595.21 (+0.63%)
DOW   35,874.10 (+0.37%)
QQQ   381.59 (+0.97%)
AAPL   149.94 (+0.87%)
MSFT   311.73 (+1.17%)
FB   320.73 (-2.42%)
GOOGL   2,779.60 (+1.12%)
TSLA   1,044.00 (+1.87%)
AMZN   3,404.60 (+2.54%)
NVDA   248.31 (+7.19%)
BABA   170.91 (-2.99%)
NIO   41.36 (+0.22%)
CGC   13.40 (-1.25%)
GE   108.13 (+2.69%)
AMD   125.38 (+2.47%)
MU   69.14 (+0.55%)
T   25.50 (-0.55%)
F   15.90 (-0.63%)
ACB   7.06 (-1.67%)
DIS   172.42 (+0.24%)
PFE   43.27 (+0.28%)
BA   212.31 (-0.26%)
AMC   36.26 (-1.55%)
S&P 500   4,595.21 (+0.63%)
DOW   35,874.10 (+0.37%)
QQQ   381.59 (+0.97%)
AAPL   149.94 (+0.87%)
MSFT   311.73 (+1.17%)
FB   320.73 (-2.42%)
GOOGL   2,779.60 (+1.12%)
TSLA   1,044.00 (+1.87%)
AMZN   3,404.60 (+2.54%)
NVDA   248.31 (+7.19%)
BABA   170.91 (-2.99%)
NIO   41.36 (+0.22%)
CGC   13.40 (-1.25%)
GE   108.13 (+2.69%)
AMD   125.38 (+2.47%)
MU   69.14 (+0.55%)
T   25.50 (-0.55%)
F   15.90 (-0.63%)
ACB   7.06 (-1.67%)
DIS   172.42 (+0.24%)
PFE   43.27 (+0.28%)
BA   212.31 (-0.26%)
AMC   36.26 (-1.55%)
S&P 500   4,595.21 (+0.63%)
DOW   35,874.10 (+0.37%)
QQQ   381.59 (+0.97%)
AAPL   149.94 (+0.87%)
MSFT   311.73 (+1.17%)
FB   320.73 (-2.42%)
GOOGL   2,779.60 (+1.12%)
TSLA   1,044.00 (+1.87%)
AMZN   3,404.60 (+2.54%)
NVDA   248.31 (+7.19%)
BABA   170.91 (-2.99%)
NIO   41.36 (+0.22%)
CGC   13.40 (-1.25%)
GE   108.13 (+2.69%)
AMD   125.38 (+2.47%)
MU   69.14 (+0.55%)
T   25.50 (-0.55%)
F   15.90 (-0.63%)
ACB   7.06 (-1.67%)
DIS   172.42 (+0.24%)
PFE   43.27 (+0.28%)
BA   212.31 (-0.26%)
AMC   36.26 (-1.55%)
S&P 500   4,595.21 (+0.63%)
DOW   35,874.10 (+0.37%)
QQQ   381.59 (+0.97%)
AAPL   149.94 (+0.87%)
MSFT   311.73 (+1.17%)
FB   320.73 (-2.42%)
GOOGL   2,779.60 (+1.12%)
TSLA   1,044.00 (+1.87%)
AMZN   3,404.60 (+2.54%)
NVDA   248.31 (+7.19%)
BABA   170.91 (-2.99%)
NIO   41.36 (+0.22%)
CGC   13.40 (-1.25%)
GE   108.13 (+2.69%)
AMD   125.38 (+2.47%)
MU   69.14 (+0.55%)
T   25.50 (-0.55%)
F   15.90 (-0.63%)
ACB   7.06 (-1.67%)
DIS   172.42 (+0.24%)
PFE   43.27 (+0.28%)
BA   212.31 (-0.26%)
AMC   36.26 (-1.55%)
ASX:CUV

Clinuvel Pharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume124,193 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.06%
BetaN/A

Receive CUV News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRÃNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$47.98 million
Book Value
A$2.00 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.02 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Clinuvel Pharmaceuticals (ASX:CUV) Frequently Asked Questions

What stocks does MarketBeat like better than Clinuvel Pharmaceuticals?

Wall Street analysts have given Clinuvel Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clinuvel Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How often does Clinuvel Pharmaceuticals pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals declared a Interim dividend on Friday, August 27th. Stockholders of record on Thursday, September 16th will be paid a dividend of 0.025 per share on Thursday, September 16th. This represents a dividend yield of 0.07%. The ex-dividend date of this dividend is Wednesday, September 1st.
View Clinuvel Pharmaceuticals' dividend history
.

Is Clinuvel Pharmaceuticals a good dividend stock?

Clinuvel Pharmaceuticals pays an annual dividend of A$0.03 per share and currently has a dividend yield of 0.06%. The dividend payout ratio of Clinuvel Pharmaceuticals is 6.20%. This payout ratio is at a healthy, sustainable level, below 75%.
View Clinuvel Pharmaceuticals' dividend history.

Who are Clinuvel Pharmaceuticals' key executives?

Clinuvel Pharmaceuticals' management team includes the following people:
  • Dr. Philippe Jacques Wolgen M.B.A., MBA, M.D., CEO, MD & Director (Age 58, Pay $1.73M)
  • Mr. Darren M. Keamy, CFO & Company Sec. (Age 48, Pay $372.08k)
  • Dr. Dennis J. Wright, Chief Scientific Officer
  • Mr. Malcolm Bull, Head of Investor Relations
  • Lachlan Hay, Gen. Mang. of Europe

What other stocks do shareholders of Clinuvel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinuvel Pharmaceuticals investors own include Zynga (ZNGA), Worldpay (WP), VolitionRx (VNRX), REA Group (REA), CSL (CSL), Cochlear (COH), (CATB) and Afterpay (APT).

What is Clinuvel Pharmaceuticals' stock symbol?

Clinuvel Pharmaceuticals trades on the ASX under the ticker symbol "CUV."

How much money does Clinuvel Pharmaceuticals make?

Clinuvel Pharmaceuticals has a market capitalization of $0.00 and generates $47.98 million in revenue each year.

What is Clinuvel Pharmaceuticals' official website?

The official website for Clinuvel Pharmaceuticals is www.clinuvel.com.

How can I contact Clinuvel Pharmaceuticals?

The company can be reached via phone at 61 3 9660 4900.


This page was last updated on 10/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.